diosmin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	3157	520-27-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

diosmin
barosmin
diosmil
diosmine
flebosten
flebosmil

A bioflavonoid that strengthens vascular walls.

Molecular weight: 608.55
Formula: C28H32O15
CLOGP: 0.23
LIPINSKI: 3
HAC: 15
HDO: 8
TPSA: 234.29
ALOGS: -2.60
ROTB: 7

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tubulointerstitial nephritis and uveitis syndrome	67.86	34.67	10	1072	235	63487705
Erysipelas	65.51	34.67	17	1065	7888	63480052
Myoglobin blood increased	44.42	34.67	9	1073	1396	63486544
Delirium	37.71	34.67	18	1064	50523	63437417
Hypercapnia	36.96	34.67	10	1072	5421	63482519

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood lactic acid	95.49	48.84	14	561	332	34956024

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood lactic acid	87.64	30.61	14	1690	449	79742235
Tubulointerstitial nephritis and uveitis syndrome	62.46	30.61	10	1694	325	79742359
Erysipelas	56.33	30.61	17	1687	10833	79731851
Ventricular tachycardia	36.98	30.61	18	1686	41917	79700767
Myoglobin blood increased	35.15	30.61	9	1695	3142	79739542
Hypercapnia	33.82	30.61	11	1693	8924	79733760
Lentigo maligna	31.31	30.61	6	1698	556	79742128

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C05CA03	CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids
ATC	C05CA53	CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:67079	anti-inflammatory agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.73	acidic
pKa2	10.43	acidic
pKa3	12.32	acidic
pKa4	13.05	acidic
pKa5	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Inhibitor of nuclear factor kappa-B kinase subunit beta	Kinase	O14920	IKKB_HUMAN		IC50	5.41		CHEMBL
Lysine-specific histone demethylase 1A	Enzyme	O60341	KDM1A_HUMAN		IC50	4.99		CHEMBL

External reference:

ID	Source
N0000167025	NUI
D07858	KEGG_DRUG
4036523	VANDF
C0012498	UMLSCUI
CHEBI:4631	CHEBI
CHEMBL231884	ChEMBL_ID
D004145	MESH_DESCRIPTOR_UI
DB08995	DRUGBANK_ID
4370	INN_ID
7QM776WJ5N	UNII
5281613	PUBCHEM_CID
3489	RXNORM
005803	NDDF
126142004	SNOMEDCT_US
8143001	SNOMEDCT_US

Pharmaceutical products:

None